Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Postpartum Depression, Heart Rate Variab...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Perinatal depression is a highly prevalent and serious health issue during pregnancy. According to statistics, approximately one out of every ten postpartum women experiences this condition. Symptoms can manifest as mood fluctuations or emotional lows. Unfortunately, these symptoms are often overlooked by patients themselves or misinterpreted by others as normal adjustments to the new role of motherhood. Consequently, timely assistance and support are frequently lacking. To address this, the investigators urgently need effective preventive measures for perinatal depression before it escalates. Recent research suggests that simple oral supplementation of vitamin B6 may help prevent and alleviate perinatal depression to some extent. Vitamin B6 plays several crucial roles in the body, including regulating neurotransmission and mental health. Therefore, it could contribute to maintaining emotional stability and psychological balance. In contemporary times, numerous screening methods for perinatal depression involve questionnaires. However, these methods presuppose an awareness of the possibility of perinatal depression. Individuals who are unaware of these questionnaires may go undetected. Hence, our aim is to investigate whether cardiac electrophysiology results obtained through a wearable device could offer a more objective evaluation of the status of perinatal depression. Our plan involves conducting a prospective study to delve deeper into the preventive and therapeutic effects of vitamin B6 on perinatal depression in pregnant women. Through systematic experiments and data analysis, the investigators aim to explore the impact of vitamin B6 dosage, duration, and timing of administration. Ultimately, the investigators hope to provide evidence-based recommendations and guidance for clinical practice. The investigators' goal is to offer new insights and methods to protect the mental health of expectant mothers, ensuring a pleasant and healthy pregnancy journey for each one.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Combination Product: Vitamin B6 — The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
  • Combination Product: Placebo — Placebo

Primary Outcomes

  • Number of participants with GAD-2(General Anxiety Disorder-2) score≥3 and EPDS(Edinburgh Postnatal Depression Scale)≥10. (22 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-05
Completion: 2026-09-30
Eligibility
Age: 20 Years – 50 Years
Sex: FEMALE
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Principal Investigators:
  • HanYing Chen (PRINCIPAL_INVESTIGATOR) - Attending physician
Contact Information
Study Contact:
HanYing Chen
886-930078287
hanyingchan@Hotmail.com
Han-Ying Chen
0930078287
National Taiwan University Hospital
Interventions
  • Combination Product: Vitamin B6 — The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
  • Combination Product: Placebo — Placebo
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: * Pregnant women at 24-28 weeks of gestation * Without a personal history of depression, bipolar disorder, schizophrenia, or other mental health conditions. Exclusion Criteria: * Allergic to Vitamin B6

iTBS+D-Cycloserine for Youth Suicide

NCT06121284
Recruiting
Conditions Suicidal Ideation, Suicide, Attempted, D...
Phase PHASE2
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives. Transcranial Magnetic Stimulation (TMS) is a non-invasive neurostimulation treatment for major depressive disorder, a mental health condition at high risk for suicide. It is well tolerated and effective. However, in the child and youth population, it does not appear to be superior to sham-TMS. Therefore, strategies for enhancing TMS outcomes are required. Over time, TMS can change the function of brain regions important in depression to reduce the symptoms of depression, including suicidal ideation. The investigators believe this occurs through a process called 'synaptic plasticity', or the process by which neurons change their connectivity with other neurons in an activity-dependent manner. Using an adjunct to facilitate these changes in the EA population may improve TMS outcomes, including both implicit and explicit measures of suicide risk. The investigators\' previous data indicates that, in adults, the effects of a TMS protocol called intermittent theta-burst stimulation (iTBS) can be enhanced by pairing stimulation with a medication called D-Cycloserine. This FDA-approved medication leads to enhanced synaptic plasticity with iTBS. In adults, this combination led to greater improvements in depression symptoms and both implicit and explicit suicide risk. Implicit suicide risk is measured with a computerized test, called the death/suicide implicit association test (Death/Suicide IAT), and explicit suicide risk is defined as suicidal thoughts reported by the individual. In the current study, we aim to determine whether the effects of iTBS can be augmented with D-Cycloserine to reduce suicide risk in the EA population. Typical courses of iTBS involve daily treatments over 6 weeks, a timeframe that is not acceptable in individuals experiencing suicidal ideation. For this reason, we will build on data indicating that treatment courses can be condensed by delivering multiple treatments in a single day to accelerate symptomatic improvements. Specifically, our data suggests that (1) 4-weeks of daily iTBS+D-Cycloserine significantly improves implicit and explicit suicide risk and (2) a single-dose of D-Cycloserine paired with two iTBS treatments separated by one hour, enhances the physiological effects of iTBS. As such, in this study, participants will receive two treatments per day, separated by an hour, thereby accelerating a typical 4-week course to 2 weeks. Research Question and Objectives: To conduct a 2-week double-blind placebo-controlled randomized clinical trial where 54 participants will be randomly assigned to one of two groups: 1) accelerated iTBS+D-Cycloserine, and 2) accelerated iTBS+placebo. The primary outcome of the study is performance on the Death/Suicide-IAT, a measure of suicide risk; however…

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: D-Cycloserine — Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
  • Device: intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation — Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
  • Drug: Placebo oral tablet — Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.

Primary Outcomes

  • Performance on the Death Implicit Association Test (D-IAT) at treatment end (Change from baseline to end of treatment (week 2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-11
Completion: 2026-09
Eligibility
Age: 18 Years – 24 Years
Sex: ALL
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Calgary
Collaborators: University of Alberta
Principal Investigators:
  • Alexander McGirr, MD PhD (PRINCIPAL_INVESTIGATOR) - University of Calgary
Contact Information
Study Contact:
Alexander McGirr, MD PhD
403 210 6410
alexander.mcgirr@ucalgary.ca
Alexander McGirr, MD PhD
4032106410
alexander.mcgirr@ucalgary.ca
University of Calgary
Interventions
  • Drug: D-Cycloserine — Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
  • Device: intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation — Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
  • Drug: Placebo oral tablet — Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
Study Locations (1 sites)
University of Calgary, Calgary, Alberta T2N 1N4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged 18 to 24 years 2. Any sex or gender 3. Are competent to consent to treatment 4. Have previously attempted suicide as defined by the Columbia Suicide Severity Rating Scale 5. Currently have suicidal ideation as defined by a score ≥4 on item 10 of the MADRS in the past week. Individuals with active suicidal ideation, defined as suicidal ideation with the intention to act on a plan that might result in death, are only eligible if currently hospitalized 6. Moderate depression measured on the 17-item Hamilton Rating Scale for Depression (HAMD-17) ≥15 7. Are able to adhere to the treatment schedule 8. Pass the TMS adult safety screening (TASS) questionnaire 9. Have a normal ECG, CBC, electrolytes, BUN, creatinine, eGFR, AST, ALT, and GGT within the last month. Exclusion Criteria: 1. Allergy to cycloserine or any excipients due to possible anaphylaxis or other reactions. 2. Current alcohol or substance misuse. 3. Current symptoms or history of psychosis, as this can be aggravated by D-Cycloserine. 4. Are currently pregnant, breast feeding or plan to become pregnant during the study, as the effects of D-Cycloserine on the fetus are unknown. Health Canada requires that women of reproductive potential utilize either highly effective birth control or double barrier method of contraception. Abstinence is only acceptable when it is the usual and preferred lifestyle of the participant. 5. Have failed a course of ECT in the current episode. Previous ECT treatment outside of the current episode does not influence inclusion. 6. Have previously failed a course of rTMS treatment 7. Have any significant neurological disorder or insult as this increased the risk of adverse events with rTMS including, but not limited to any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of epilepsy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 15 minutes 8. Have concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump 9. Have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed because these can heat or move due to the rapidly alternating magnetic field generated by rTMS. 10. Are currently being treated with GABA agonists such as benzodiazepines, cyclopyrrolones, gabapentin/pregabalin, or anticonvulsant due to the potential to limit TMS efficacy 11. Those with a history of intracranial implants or metal, or with any potential metal fragments in the body (particularly in the orbits).
Conditions Major Depressive Disorder
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control, non-depressed subjects.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: NIRSIT — NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.

Primary Outcomes

  • Change in Frontal Oxyhemoglobin concentration before initiation of treatment for MDD (Each measurement is over 10 to 15 mins long, taken during the performance of VFT and CHR, on the day of initiation of treatment for MDD, but before the treatment is given.)
  • Change in Frontal Oxyhemoglobin concentration 3 weeks after initiation of treatment for MDD (Each measurement is over 10 to 15 mins long, taken during the performance of VFT and CHR, 3 weeks after initiation of treatment for MDD.)
  • Change in Frontal Oxyhemoglobin concentration 6 weeks after initiation of treatment for MDD (Each measurement is over 10 to 15 mins long, taken during the performance of VFT and CHR, 6 weeks after initiation of treatment for MDD.)
  • Change in Frontal Deoxyhemoglobin concentration before initiation of treatment for MDD (Each measurement is over 10 to 15 mins long, taken during the performance of VFT and CHR, on the day of initiation of treatment for MDD, but before the treatment is given.)
  • Change in Frontal Deoxyhemoglobin concentration 3 weeks after initiation of treatment for MDD (Each measurement is over 10 to 15 mins long, taken during the performance of VFT and CHR, 3 weeks after initiation of treatment for MDD.)
  • Change in Frontal Deoxyhemoglobin concentration 6 weeks after initiation of treatment for MDD (Each measurement is over 10 to 15 mins long, taken during the performance of VFT and CHR, 6 weeks after initiation of treatment for MDD.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-01-04
Completion: 2030-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: OBELAB, Inc., San Francisco Veterans Affairs Medical Center
Principal Investigators:
  • Arthur Wallace, MD, PhD (PRINCIPAL_INVESTIGATOR) - San Francisco Veterans Affairs Medical Center
Contact Information
Study Contact:
Anusha Badathala, MBBS
4152214810
Anusha.Badathala@ncire.org
Arthur Wallace, MD, PhD
4152214810
art.wallace@va.gov
Arthur Wallace, MD, PhD
San Francisco Veterans Affairs Medical Center
Interventions
  • Device: NIRSIT — NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
Study Locations (1 sites)
San Francisco Veterans Affairs Medical Center, San Francisco, California 94121 United States
Eligibility Criteria
Inclusion Criteria: * All subjects who sign informed consent. * Controls: Volunteers over 18 years of age who are not depressed. * Patients over 18 years of age with a diagnosis of Major Depressive Disorder, receiving clinical therapy at SFVAMC. Exclusion Criteria: * Subjects who cannot sign informed consent. * Exclusion criteria for control subjects: 1.Depression 2.Anxiety, psychotic, substance abuse, mood and personality disorders 3.Major neurocognitive disorders such as Alzheimer's disease and other dementias 4.Neurologic disorders with anatomic lesions including traumatic brain injury, stroke, tumor and arteriovenous malformation * Exclusion criteria for depressed patients: 1.Psychotic disorders like schizophrenia 2.Major neurocognitive disorders such as Alzheimer's disease and other dementias 3.Neurologic disorders with anatomic lesions including traumatic brain injury, stroke, tumor and arteriovenous malformation 4.Not receiving clinical therapy for depression at SFVAMC'
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 116
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing overweight or obesity. The treatment will be an add-on treatment to the patient's usual medication. The investigators hypothesize that adjunctive treatment with semaglutide, will lead to a significant improvement in mood compared to placebo in patients with MDD and overweight or obesity. The primary endpoint is the change in depressive symptoms measured as difference in the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from start to follow-up after 26 weeks. The MDI measures the extent to which symptoms of depression have been present in the past two weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Semaglutide Injectable Product — Semaglutide (Wegovy) once-weekly injection s.c
  • Drug: Placebo — Placebo (BD Posiflush) once-weekly injection s.c

Primary Outcomes

  • Change in depressive symptoms (From baseline to 26 weeks of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-09-11
Completion: 2027-09
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nordsjaellands Hospital
Principal Investigators:
  • Maj Vinberg, MD, PhD, DMSc (PRINCIPAL_INVESTIGATOR) - Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Contact Information
Study Contact:
Maj Vinberg, MD, DMSc
+ 45 38 64 32 27
maj.vinberg@regionh.dk
Christoffer Stanislaus, MD, ph.d.-student
Christoffer.stanislaus@regionh.dk
Maj Vinberg, MD, DMSc, Professor
+45 38643227
Maj.Vinberg@regionh.dk
Mental Health Centre North Zealand
Interventions
  • Drug: Semaglutide Injectable Product — Semaglutide (Wegovy) once-weekly injection s.c
  • Drug: Placebo — Placebo (BD Posiflush) once-weekly injection s.c
Study Locations (1 sites)
Mental Health Centre North Zealand, Hillerød, Denmark 3400 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Informed oral and written consent. 2. Diagnosed with unipolar disorder according to the criteria of ICD10 (International Classification of Diseases, World Health Organization (WHO)) or the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the American Psychiatric Association 3. Hamilton Depression Rating Scale, 17-items (HDRS-17)47 score ≥14, 4. Age 18 years to 65 years (both included) 5. Body mass index (BMI) ≥27 kg/m2 6. Able to speak and understand Danish Exclusion Criteria: 1. Any significant medical disorder or conditions that contraindicate the investigational drug, e.g., pregnancy, presence of known allergy GLP-1 receptor agonists, severe neurological disorder, on-going drug, or alcohol abuse 2. Coercive measures 3. Females of childbearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant within the next 9 months (26 weeks plus two months after discontinuation of semaglutide), or are not using contraceptives (during the whole study period) considered as highly effective (combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) intrauterine device - IUD, IUS, bilateral tubal occlusion, vasectomised partner, sexual abstinence) 4. Patients treated with corticosteroids or other hormone therapy (except oestrogens). 5. Any active substance abuse or dependence (except for nicotine) 6. Impaired hepatic function (plasma liver transaminases \>2 times upper normal limit). 7. Impaired renal function (serum creatinine \>150 μmol/l) 8. Cardiac problems defined as decompensated heart failure (NYHA class III/IV), unstable angina pectoris, and/or myocardial infarction within the last 12 months 9. Hypertension with systolic blood pressure \>180 mmHg or diastolic blood pressure \>100 mmHg 10. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase \>2 times upper normal limit). Receiving any experimental or pre-marketing drug within the last 3 months 11. Use of diabetes medication or weight-lowering pharmacotherapy e.g. semagultid within the preceding 3 months 12. Known type 1 and 2 diabetes or HbA1c\>48mmol/l 13. Suicidal behaviour as judged by the investigator and based on clinical evaluation. At all contact with patient attendance (please see Table 1) possible suicidality will be evaluatedaccording to the guidelines. If the patient is evaluated as suicidal, the person will be excluded from the study and evaluated by a senior consultant in psychiatry, who will take further action. 14. Any condition that the investigator feels would interfere with trial participation.
Conditions Child Behavior, Mental Health Issue, Psy...
Phase NA
Enrollment 312
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Purpose: The purpose of this research is to pilot test a novel, alternative, potentially sustainable system of teacher-delivered, task-shifted child mental health care. Participants: \~300 estimated Procedures: This is a RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) guided, mixed methods, clustered evaluation of Tealeaf-NC's Reach, Adoption \& Implementation (Primary Outcomes, implementation-based), as well as evaluating for preliminary indicators of Effectiveness \& Maintenance (Secondary Outcomes, clinically-based).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Teachers Leading the Frontlines — 1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention. 2. The teachers select students whom they believe have the highest mental health needs to receive care. 3. Teachers analyze chosen students' symptoms. 4. Teachers analyze students' behavior with the AABC Chart. 5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior. 6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home.
  • Behavioral: Responding to Students' Emotions Through Education — All processes for RE-SEED are the same as in Tealeaf except... 1. Teachers receive only 1 day of training 2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students.

Primary Outcomes

  • Mean Acceptability of Intervention Measure (AIM) Scores (Month 0, Month 9)
  • Mean Intervention Appropriateness Measure (IAM) Scores (Month 0, Month 9)
  • Mean Feasibility of Intervention Measure (FIM) Scores (Month 0, Month 9)
  • Mean Cause Analysis Chart (AABC) Evaluation Checklist Scores (Month 9)
  • Mean 4Cs Behavior Plan Evaluation Checklist Scores (Month 9)
  • Mean One-on-One Student Interaction Evaluation Tool Scores (Month 9)
  • Mean One-on-One Family Interaction Evaluation Tool Scores (Month 9)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-08
Completion: 2027-06
Eligibility
Age: 5 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 312 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: Darjeeling Ladenla Road Prerna, Broadleaf Health and Education Alliance, University of Colorado, Denver, Doris Duke Charitable Foundation
Principal Investigators:
  • Christina R Cruz, MD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Christina Cruz, MD
347-721-1458
christina_cruz@med.unc.edu
Michael Matergia, MD
857-488-7209
michael.matergia@broadleafhea.org
Christina M Cruz, MD
347-721-1458
christina_cruz@med.unc.edu
University of North Carolina at Chapel Hill
Interventions
  • Behavioral: Teachers Leading the Frontlines — 1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention. 2. The teachers select students whom they believe have the highest mental health needs to receive care. 3. Teachers analyze chosen students' symptoms. 4. Teachers analyze students' behavior with the AABC Chart. 5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior. 6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home.
  • Behavioral: Responding to Students' Emotions Through Education — All processes for RE-SEED are the same as in Tealeaf except... 1. Teachers receive only 1 day of training 2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students.
Study Locations (1 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514 United States
Eligibility Criteria
Inclusion Criteria: Schools: * Have been trained in either Tealeaf or RE-SEED in Summer 2024 or 2025 after being randomized programmatically * Be a school in the State of North Carolina * Have an eligible principal Principals: * \>18 years old * Employed at an enrolled school * Not suspected or convicted of child-related misconduct or maltreatment Teachers: * \>18 years old * Employed at an enrolled school * Primary teaching responsibility for a single academic class (for a minimum of 1 hour per day and a minimum of 4 days per week) in any grade level Kindergarten to Grade 8 * Not suspected or convicted of child-related misconduct or maltreatment Counselors: * \>18 years old * Employed at an enrolled school * Hold a school counselor position at an enrolled school for at least 10 hours per week * Not suspected or convicted of child-related misconduct or maltreatment Students: * Enrolled in Kindergarten-Grade 8 * Student of an enrolled teacher * Has a parent or guardian who can provide consent * Positive/Clinical-level score on the Strengths and Difficulties Questionnaire (SDQ) Guardians: * \>18 years old * Guardian of enrolled student Exclusion Criteria: * Exclusion criteria will be set as each participant does not meet the inclusion criteria as set for their group.
Conditions Major Depressive Disorder (MDD)
Phase PHASE3
Enrollment 388
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive disorder.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Dextromethorphan and Bupropion Sustained-Release Tablets — Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.
  • Drug: Placebo — Oral placebo tablets, taken daily for 6 weeks.

Primary Outcomes

  • Change in MADRS Total Score From Baseline to Week 6 (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-04-11
Completion: 2026-12-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 388 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Clinical Trials Information Group officer
86-0311-69085587
ctr-contact@cspc.cn
Gang Wang, Ph.D
86-010-86430066
adyywmb@126.com
Beijing Anding Hospital Affiliated to Capital Medical University
Interventions
  • Drug: Dextromethorphan and Bupropion Sustained-Release Tablets — Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.
  • Drug: Placebo — Oral placebo tablets, taken daily for 6 weeks.
Study Locations (1 sites)
Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality 100088 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female, Age 18 - 65, inclusive 2. Currently meets DSM-5 diagnosis of MDD without psychotic features, Current major depressive episode of at least 4 weeks in duration at screening 3. Identified as MDD by Mini-international Neuropsychiatric interview (M.I.N.I.) 4. MADRS score ≥25 and CGI-S ≥4 at screening and baseline 5. The results of physical examination and laboratory tests during the screening period meet the test requirements 6. Body Mass Index between 18 and 40 kg/m2, inclusive 7. For male subjects, use of an adequate method of birth control by the subject and by female sexual partners Exclusion Criteria: * 1\. The researchers determined that it was refractory depression \[defined as in a current depressive episode or a previous depressive episode, After 2 or more antidepressants, a sufficient amount (in the maximum recommendation of the manual), a course of foot therapy (at least even Continued medication for 4-6 weeks) ineffective after treatment\] 2. The MADRS score improved by ≥ 25% at baseline compared with the screening period. 3\. Hospitalization in a psychiatric hospital during a current depressive episode 4. There is a clinically significant risk of suicide or self-harm and harm to others 5. Screening patients tested positive for substance abuse 6. In the investigator's judgment, there are any clinically significant oncology, hematology, or internal diseases that are not suitable for entry into the study Secretory/metabolic, cardiovascular, respiratory, kidney, liver, gastrointestinal, infectious or nervous system fever Or suffer from an unstable or progressive chronic disease 7. hypertension 8. Hypothyroidism or hyperthyroidism, except for the following cases: receiving stable medication with no change in dose for at least 1 month before screening (serum TSH must be \> 0.75×LLN( Lower Limit of Normal ) and \< 1.25×ULN(Upper Limit of Normal )) 9 Bupropion, dextromethorphan, opioids (such as codeine), or any of the study drugs Allergic to other ingredients 10. Presence of a history of intolerance to bupropion or dextromethorphan 11. People living with HIV, or testing positive for HIV during screening 12. Screening period hepatitis virology test positive 13. Liver enzyme test results during the screening period (total bilirubin, aspartate aminotransferase and/or alanine aminotransferase) \> 2.0 × ULN 14. According to the investigator's judgment, other conditions are not suitable for participating in this clinical study
Conditions Stroke
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a music-based telerehabilitation intervention implemented at home works to treat different kinds of neurological deficits caused by stroke. The main questions it aims to answer are: 1) Can the music intervention improve recovery of cognitive, verbal, motor, and emotional deficits after stroke, 2) can the music intervention enhance structural and functional recovery of the brain, and (3) how different demographic, musical, and clinical background factors affect the way the music intervention works. Researchers will compare the music intervention to standard (usual) care to see if the music intervention works to treat the deficits caused by stroke. Subjects are stroke patients who will participate either in the music intervention 5 times/week for 10 weeks in addition to standard care or receive standard care only. During the trial, the subjects will undergo neuropsychological testing and magnetic resonance imaging (MRI) three times: at baseline (before the intervention), at 3-month stage (immediately after the intervention), and at 6-month stage (3 months after the intervention).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Music-based telerehabilitation — The music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min).

Primary Outcomes

  • Change in the cognitive functioning summary score from baseline to 3-month stage (Baseline and 3-month stage)
  • Change in the speech production summary score from baseline to 3-month stage (Baseline and 3-month stage)
  • Change in the upper-extremity motor function summary score from baseline to 3-month stage (Baseline and 3-month stage)
  • Change in the mood and quality of life summary score from baseline to 3-month stage (Baseline and 3-month stage)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2028-12
Eligibility
Age: 30 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Teppo Sarkamo
Collaborators: HUS Neurocenter, HUS Medical Imaging Centre, University of Jyvaskyla, Finnish Brain Association, Uusimaa Stroke Association
Principal Investigators:
  • Teppo Särkämö, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Helsinki / Faculty of Medicine / Department of Psychology
Contact Information
Study Contact:
Teppo Särkämö, Ph.D.
+358505399065
teppo.sarkamo@helsinki.fi
Nella Moisseinen, M.A.
+358504070507
nella.moisseinen@helsinki.fi
Nella Moisseinen, M.A.
+358504070507
nella.moisseinen@helsinki.fi
University of Helsinki / Faculty of Medicine / Department of Psychology
Interventions
  • Behavioral: Music-based telerehabilitation — The music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min).
Study Locations (1 sites)
University of Helsinki / Faculty of Medicine / Department of Psychology, Helsinki, 00014 Finland
Eligibility Criteria
Inclusion Criteria: * Left or right hemisphere stroke which has occurred at least 3 months ago * At least mild cognitive deficit and mild aphasia / upper-extremity hemiparesis caused by the stroke * Age 30-80 years * Finnish-speaking (or bilingual, able to participate in Finnish) * Understands the purpose of the study and is able to give informed consent Exclusion Criteria: * Prior significant hearing or visual impairment * Prior severe psychiatric illness (e.g., schizopheria, bipolar disorder, severe unipolar depression) * Prior severe neurological illness (e.g., brain injury, dementia; can have prior TIA or mild stroke)
Conditions Treatment Resistant Depression
Phase NA
Enrollment 108
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

INTRODUCTION Recent findings from three small studies (total n=59) suggest that three changes in repetitive Transcranial Magnetic Stimulation (rTMS) protocols, called the Stanford Neuromodulation Therapy (SNT) protocol, contribute to extreme high overall remission of 79% in patients with treatment resistant depression (TRD), whereas remission using a standard 10 Hz rTMS protocol is 25%. The improvement using the SNT protocol is achieved by combining 1) accelerated treatment with multiple sessions per day, 2) applying a higher overall pulse dose of stimulation, using intermittent Theta Burst Stimulation (iTBS), and 3) precise targeting of the region in the left dorsolateral prefrontal cortex (DLPFC), using functional MRI guided neuronavigation. OBJECTIVE To determine if the SNT protocol is more (cost-) effective compared to standard 10 Hz rTMS in patients with TRD, even though the number of pulses given in both protocols is equal, i.e., 90,000. STUDY DESIGN Multicenter randomized controlled trial comparing SNT with standard 10Hz rTMS with a follow-up of 25 weeks. STUDY POPULATION 108 Patients with TRD (no response to 2 or more evidence-based treatments). INTERVENTION 50 sessions using the SNT protocol in 5 days. The region of the left DLPFC most anticorrelated with the subgenual anterior cingulate cortex in each participant will be targeted based on subject-specific functional resting state MRI. COMPARISON 30 standard daily 10 Hz rTMS sessions in six weeks, targeting the left DLPFC based on standard measurement procedures of the skull. OUTCOME MEASURES * Remission, based on the Hamilton depression rating scale * Cost effectiveness, based on healthcare resource use * Quality of life and positive mental health * Tolerability and safety * Relapse * Description of opportunities and difficulties with regard to implementation SAMPLE SIZE The investigators will enrol 108 patients (α=0.05, power is 0.80) including adjustment for attrition. COST EFFECTIVENESS ANALYSIS SNT is faster and possibly more effective than 10Hz rTMS leading to a total cost reduction of 22 million each year considering less expensive healthcare, reduced illness duration and absence from work. TIME SCHEDULE Within 36 months, the investigators will recruit and treat 108 patients with TRD: each center will recruit 9 patients per year. After the last follow-up assessments, the investigators will finalise the study within 12 months and report the results.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: rTMS — 10 Hz repetitive-transcranial-magnetic-stimulation
  • Device: iTBS — neuronavigated intermittent theta burst transcranial-magnetic-stimulation

Primary Outcomes

  • Remission (After 1 week.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-15
Completion: 2027-12
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amsterdam UMC, location VUmc
Collaborators: Radboud University Medical Center, Maastricht University Medical Center, Maastricht University, Trimbos, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Donders Centre for Neuroscience
Contact Information
Study Contact:
Annemiek Dols, MD PhD
0610445878
a.dols@amsterdamumc.nl
Eric van Exel, MD PhD
+31204444444
e.vexel@amsterdamumc.nl
Philip van Eijndhoven
philip.vaneijndhoven@radboudumc.nl
Radboud UMC
Interventions
  • Device: rTMS — 10 Hz repetitive-transcranial-magnetic-stimulation
  • Device: iTBS — neuronavigated intermittent theta burst transcranial-magnetic-stimulation
Study Locations (4 sites)
Radboud UMC, Nijmegen, GL 6525GA Netherlands
GGZinGeest, Amsterdam, North Holland 1081JC Netherlands
Amsterdam UMC location AMC, Amsterdam-Zuidoost, North Holland 1105AZ Netherlands
Maastricht UMC, Maastricht, Netherlands
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older; * Sufficient level of spoken and written Dutch; * Ability to freely provide written informed consent; * Current DSM-5 diagnosis of a depressive episode, ascertained by the Mini International Neuropsychiatry Interview (MINI-S). * A Hamilton depression rating score (HDRS) of \>16 points: this score will be obtained from the SIGH-ADS, a depression rating scale able to determine the HDRS score and a score for atypical depression. * have a treatment resistant depression, defined according to the criteria of Conway, that is, lack of remission for eight consecutive weeks after two different evidence-based treatments anti-depressant medication has to be adequately dosed(7,24). * Stable anti-depressant medication 6 weeks prior to study. Benzodiazepines may be used up to a dosage equivalent of 3.0 mg lorazepam, and can be lowered over time during the study based on clinical judgement. Exclusion Criteria: * \- Bipolar disorder. * Current psychotic disorder¸ including psychotic depression, assessed by treating psychiatrist. * Suspected dementia, assessed with a dementia screening tool, i.e., the Montreal Cognitive Assessment (MOCA)(25), with a score of less than 20 points, or a clinical suspicion of dementia, or neuroimaging indication for neurodegeneration with a Fazekas \> 1 and MTA \>1. These cut-offs ensure exclusion of patients with (preclinical) dementia. * Active suicidal thoughts and intent to act on it, assessed at the baseline interview and before the start of the trial. This assessment is based on the Columbia suicide severity rating scale, i.e., question 5 is answered positive "Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?" (26). * Metallic devices implanted above the neck, assessed at the baseline interview. * Patients diagnosed with epilepsy, by a neurologist, assessed at the baseline interview. * Substance abuse 4 weeks prior to the study, including high dosage of benzodiazepine, a dosage equivalent higher than 3.0 mg lorazepam, assessed at the baseline interview. * Inability to understand or comply with study requirements as judged by the investigators, assessed at the baseline interview. * Pregnancy
Conditions Hypertension, Autonomic Dysfunction, Ort...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to assess arterial stiffness and autonomic regulation of blood pressure and heart rate in healthy adults and people with arterial hypertension during orthostatic stress and graded physical exercise. The main objective is to analyze cardiovascular responses to exercise on a cycle ergometer in different subgroups of participants with hypertension. The study includes healthy young adults and older adults with hypertension. Participants undergo standardized assessments including orthostatic testing, graded exercise testing on a cycle ergometer, electrocardiography, and measurement of arterial stiffness parameters such as pulse wave velocity, as well as other vascular and hemodynamic parameters. The results of this study are expected to improve understanding of cardiovascular physiology and autonomic regulation in people with hypertension and may contribute to earlier recognition of autonomic dysfunction and improved clinical management.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Primary Outcomes

  • Heart Rate Variability (Baseline (Day 1 study visit))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-15
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Centre Ljubljana
Principal Investigators:
  • Amela Kabaklić, MD, PhD (PRINCIPAL_INVESTIGATOR) - University Medical Centre Ljubljana
Contact Information
Study Contact:
Amela Kabaklić, MD, PhD
+386 1 522 43 05
amela.kabaklic@kclj.si
Amela Kabaklić, MD, PhD
+386 1 522 43 05
amela.kabaklic@kclj.si
University Medical Centre Ljubljana
Timur Mušić, MD
University Medical Centre Ljubljana
Interventions
N/A
Study Locations (1 sites)
University Medical Centre Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Healthy volunteers aged 18-35 years without known acute or chronic disease, non-smokers, body mass index (BMI) 20-24.9 kg/m², and negative orthostatic test * Participants aged ≥60 years with arterial hypertension followed at the Department of Hypertension * Hypertension group: controlled arterial hypertension, negative orthostatic test, without diabetes mellitus * Hypertension with orthostatic hypotension group: controlled arterial hypertension and positive orthostatic test indicating orthostatic hypotension * Hypertension with orthostatic hypertension group: controlled arterial hypertension and positive orthostatic test indicating a rise in blood pressure during orthostatic testing * Hypertension with diabetes mellitus group: controlled arterial hypertension and diabetes mellitus without previously diagnosed autonomic dysfunction * Ability to provide written informed consent Exclusion Criteria: * Dementia, neurodegenerative disease, or cognitive impairment preventing understanding of study procedures * Known cardiovascular disease including heart failure (NYHA II-IV), myocardial infarction within the previous 6 months, clinically significant arrhythmias, or peripheral arterial occlusive disease * Uncontrolled arterial hypertension * Change in antihypertensive therapy within the previous 4 weeks * Presence of a cardiac pacemaker * Treatment with antiarrhythmic drugs (class I, III, or IV), digoxin, alpha-receptor blockers, or other medications known to significantly affect heart rate variability or autonomic function * Advanced renal failure (eGFR \<30 mL/min/1.73 m²) or advanced liver failure * Active malignancy * Body mass index ≥35 kg/m² * Acute illness within the previous 4 weeks * Current smoking * Inability to safely perform exercise testing on a cycle ergometer * Severe psychiatric disorders without stable treatment * Pregnancy or breastfeeding * Participation in another clinical study * Refusal or inability to provide written informed consent
Conditions Microalbuminuria, Microalbuminuria /Crea...
Phase NA
Enrollment 4162
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the "three highs" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death. For blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood pressure below 130 mmHg significantly reduces ASCVD events. For LDL cholesterol, "the lower, the better" applies, with guideline-recommended LDL-C targets determined by baseline ASCVD risk, with levels below 55 mg/dL for very high-risk patients. For diabetes, treatment goals generally include fasting plasma glucose below 130 mg/dL and glycated hemoglobin (HbA1c) below 7%. Although antihypertensive therapy has been proven effective in preventing cardiovascular disease and chronic kidney disease attributable to hypertension, fewer than one-third of patients receiving antihypertensive medications achieve current guideline-recommended blood pressure targets. No randomized clinical trial to date has used home blood pressure as the primary therapeutic reference. Moreover, long-term evidence is lacking regarding the organ-protective effects of strategies targeting morning hypertension and of bedtime dosing regimens. Although the TIME study is currently the largest and longest-followed trial addressing dosing time, its bedtime-dosing arm was not specifically targeted to patients with morning hypertension. Therefore, we propose a clinical trial to investigate management strategies for morning hypertension. Aligned with the 2022 Taiwan Hypertension Guidelines, we will employ the "722 protocol" for home blood pressure monitoring and enroll patients with morning home blood pressure ≥130/80 mmHg to compare selective nocturnal administration of antihypertensive agents versus exclusive morning dosing, assessing differences in morning home blood pressure control rates, end-organ damage, and atherosclerotic cardiovascular disease (ASCVD) events. This project will implement two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network. The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the "888" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Interactive digital modules — Whether the Mobile Digital Health Platform augmented with interactive digital modules improves control rates of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia), target organ damages and cardiovascular outcomes
  • Behavioral: Antihypertensive Medication Management — Therapeutic effects of selective nocturnal versus universal morning antihypertensive dosing on morning home blood pressure control and target organ damages

Primary Outcomes

  • Mean home blood pressure <130/80 mmHg. (24 months from baseline)
  • LDL-C <100 mg/dL (and <70 mg/dL for patients with diabetes or ASCVD). (24 months from baseline)
  • HbA1c <6.5% or a reduction of at least 1% from baseline if baseline HbA1c >8% or at least 2% if baseline HbA1c >10%. (24 months from base line)
  • ≥30% reduction in urine albumin to creatinine ratio (UACR). (24 months from baseline)
  • Improvement in target organ damage (changes in left ventricular mass by AI ECG and in retinal vascular lesions). (24 months from baseline)
  • • Morning home systolic and diastolic blood pressure at 6 months. (6 months)
  • • Change in UACR from baseline to 6 months, as a marker of renal target organ protection. (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-05
Completion: 2029-02-05
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 4162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: New Taipei City Medical Association
Collaborators: National Taiwan University
Contact Information
Study Contact:
Hung-Shun Yen Principal Investigator
886-22994-2075
usmg@usmg.com.tw
Tzung-Dau Wang Co-Principal Investigator
tdwang@ntu.edu.tw
Lian An Clinic
886-22998-6191
usmg@usmg.com.tw
United safety medical group(USMG)
Interventions
  • Behavioral: Interactive digital modules — Whether the Mobile Digital Health Platform augmented with interactive digital modules improves control rates of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia), target organ damages and cardiovascular outcomes
  • Behavioral: Antihypertensive Medication Management — Therapeutic effects of selective nocturnal versus universal morning antihypertensive dosing on morning home blood pressure control and target organ damages
Study Locations (1 sites)
United safety medical group(USMG), New Taipei City, Taiwan
Eligibility Criteria
Inclusion Criteria: I.T-888-DIGICARE: Eligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions: 1. Hypertension * With or without treatment, and meeting one of the following: * Office blood pressure: two consecutive measurements \>130/80 mmHg * Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of the weekly measurements exceeding this threshold 2. Hyperlipidemia * With or without treatment, and * LDL-C \>100 mg/dL (or \>70 mg/dL in patients with diabetes or established ASCVD) 3. Diabetes Mellitus * With or without treatment, and * HbA1c \>6.5% 4. Chronic Kidney Disease (CKD) * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², and * Urine albumin-to-creatinine ratio (UACR) \>30 mg/g 5. Atherosclerotic Cardiovascular Disease (ASCVD): * Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology II. DREAM-G: 1. Hypertension * With or without treatment, and meeting one of the following: * Office blood pressure: two consecutive measurements \>130/80 mmHg * Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of weekly measurements exceeding this threshold 2. Hyperlipidemia * With or without treatment, and * LDL-C \>100 mg/dL (or \>70 mg/dL in patients with diabetes or established ASCVD) 3. Diabetes Mellitus * With or without treatment, and * HbA1c \>6.5% 4. Chronic Kidney Disease (CKD) * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², and * Measurable urinary microalbumin-to-creatinine ratio 5. Atherosclerotic Cardiovascular Disease (ASCVD): • Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology Participants must meet at least one of the above chronic disease conditions and: 6. Untreated Hypertension: * Morning home blood pressure (HBP) \>130/80 mmHg: weekly average (≥4 days) \>130/80 mmHg, * Or more than half of morning HBP measurements (≥4 days per week) \>130/80 mmHg 7. Treated Hypertension: * Morning home blood pressure \>130/80 mmHg: weekly average (≥4 days) \>130/80 mmHg, * Or more than half of morning HBP measurements (≥4 days per week) \>130/80 mmHg * Average home blood pressure ≤130/80 mmHg (used to determine treatment strategy) Exclusion Criteria: I. T-888-DIGICARE 1. Symptomatic heart failure (New York Heart Association functional class II-IV) 2. End-stage renal disease requiring long-term dialysis 3. Pregnant women or those planning pregnancy II. DREAM-G: 1. Life expectancy \<1 year 2. End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care 3. Severe liver cirrhosis 4. Malignancy under active treatment
Conditions Hypertension
Phase Not Applicable
Enrollment 420
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The American College of Cardiology/American Heart Association hypertension guidelines recommend treatment initiation with dual antihypertensive therapy in adults with stage 2 hypertension (corresponding to grade 1 and 2 in the ESH classification) and an average BP \>20/10 mm Hg above target. Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). In Pakistan multiple studies were conducted on Hypertension and use of Single Pill Combination in uncontrolled Hypertension. However, no study was conducted to assess the role of Single Pill Combination (SPC) like Amlodipine and Valsartan in newly diagnosed hypertension and to assess their quality of life by patients' satisfaction with their medication after managing the hypertension with the SPC.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Fixed-Dose Combination of Amlodipine/Valsartan — Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.

Primary Outcomes

  • To assess the effectiveness of EXTOR (Amlodipine/Valsartan) in newly diagnosed hypertensive patients in 8 weeks. (8 week)
  • To assess the Health-Related Quality of Life of newly diagnosed hypertensive patients managed by Extor (8 week)
  • To assess the overall safety of EXTOR (Amlodipine/Valsartan) in newly diagnosed hypertensive patients. (8 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-28
Completion: 2025-09-15
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Searle Company Limited Pakistan
Principal Investigators:
  • Asif Mahmood, MBBS, MPH (STUDY_DIRECTOR) - The Searle Company Limited Pakistan
Contact Information
Study Contact:
ALI Y Khanzada, MBBS, MSc
922137170200
ali.yasir@searlecompany.com
Ayesha Ashal, Doctor of Pharmacy
ayesha.ashal@searlecompany.com
Abdur Rauf Prof, MBBS, FCPS, FACC, FESC
Kuwait Teaching Hospital
Interventions
  • Drug: Fixed-Dose Combination of Amlodipine/Valsartan — Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
Study Locations (2 sites)
Kuwait Teaching Hospital, Peshawar, KPK Pakistan
National Medical Centre, Karachi, Pakistan
Eligibility Criteria
Inclusion Criteria: * Patient with a clinical history of Hypertension (systolic blood pressure greater than or equal to 140 mmHg or a diastolic blood pressure greater than or equal to 90 mmHg) and never had antihypertensive treatment. * Patient aged ≥18 and ≤70 years inclusive of either sex. * Patient with ability to understand and sign written informed consent form. Exclusion Criteria: * • Patients with already on antihypertensive treatment or secondary hypertension * Pregnant women or nursing mothers * Patients with acute illnesses or psychiatric diagnosis * Known hypersensitivity to Extor product, the metabolites, or formulation excipients. * Treated with Extor to evaluate safety as per approved prescribing information for Extor in Pakistan.
Conditions Arterial Hypertension
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to develop artificial intelligence (AI) tools to characterize cardiac remodelling in arterial hypertension through the analysis of routine imaging data (echocardiography) coupled with patient data. More precisely, this study will make it possible (i) to represent in a relevant way the spectrum of the cardiac repercussions of a population affected by hypertension to better characterize the progress of the pathology, in particular vis-à-vis the more ambiguous subjects to be characterized ("grey" area); (ii) to develop tools for the automatic quantification of cardiac function (segmentation and robust monitoring of the myocardium during the cardiac cycle, for the dynamic analysis of the shape and global deformation of the heart) and therefore to extract descriptors richer in cardiac function than those currently used in clinical routine.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements) — The degree of severity of the hypertension will have been previously diagnosed for each patient with the help of the blood pressure measurements, the number of antihypertensive treatments and the NT-proBNP measurement which is correlated with the left intraventricular pressure and the mass of the left ventricle. This information will be used (i) to guide the structuring of the pathology representation space during the learning phase from a sub-population (a portion of the collected database that will be used for training algorithms); (ii) to serve as an endpoint from a test sub-population (the remaining portion of the database collected).

Primary Outcomes

  • Arterial Blood Pressure (Baseline)
  • Number of Antihypertensive Medications (Baseline)
  • NT-proBNP Concentration (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-06-01
Completion: 2024-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
PierreYves COURAND, MD
(+33) 04 78 86 57 37
pierre-yves.courand@chu-lyon.fr
Fatou LANGEVIN
(+33) 04 72 07 28 65
fatou.langevin@chu-lyon.fr
Pierre-Yves COURAND, MD, PhD
04.78.86.57.37
pierre-yves.courand@chu-lyon.fr
Hopital Lyon Sud
Interventions
  • Other: Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements) — The degree of severity of the hypertension will have been previously diagnosed for each patient with the help of the blood pressure measurements, the number of antihypertensive treatments and the NT-proBNP measurement which is correlated with the left intraventricular pressure and the mass of the left ventricle. This information will be used (i) to guide the structuring of the pathology representation space during the learning phase from a sub-population (a portion of the collected database that will be used for training algorithms); (ii) to serve as an endpoint from a test sub-population (the remaining portion of the database collected).
Study Locations (1 sites)
Hopital Lyon Sud, Pierre-Bénite, 69310 France
Eligibility Criteria
Inclusion Criteria Patients who underwent a comprehensive blood pressure assessment during hospitalization in the Cardiologic Federation at Croix Rousse Hospital and Lyon Sud Hospital between January 2018 and December 2021. Exclusion Criteria Patients who are minors. Patients under curatorship or guardianship.